Current tools for predicting cancer-specific T cell immunity

ABSTRACT Tumor exome and RNA sequencing data provide a systematic and unbiased view on cancer-specific expression, over-expression, and mutations of genes, which can be mined for personalized cancer vaccines and other immunotherapies. Of key interest are tumor-specific mutations, because T cells recognizing neoepitopes have the potential to be highly tumoricidal. Here, we review recent developments and technical advances in identifying MHC class I and class II-restricted tumor antigens, especially neoantigen derived MHC ligands, including in silico predictions, immune-peptidome analysis by mass spectrometry, and MHC ligand validation by biochemical methods on T cells.

[1]  E. Mardis,et al.  A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells , 2015, Science.

[2]  Jennifer N. Sutton,et al.  Use of selected reaction monitoring mass spectrometry for the detection of specific MHC class I peptide antigens on A3 supertype family members , 2005, Cancer Immunology, Immunotherapy.

[3]  Jimmy Lin,et al.  Mining Exomic Sequencing Data to Identify Mutated Antigens Recognized by Adoptively Transferred Tumor-reactive T cells , 2013, Nature Medicine.

[4]  J. Leunissen,et al.  The Human Leukocyte Antigen–presented Ligandome of B Lymphocytes* , 2013, Molecular & Cellular Proteomics.

[5]  Arne Elofsson,et al.  Prediction of MHC class I binding peptides, using SVMHC , 2002, BMC Bioinformatics.

[6]  Etienne Caron,et al.  Analysis of Major Histocompatibility Complex (MHC) Immunopeptidomes Using Mass Spectrometry* , 2015, Molecular & Cellular Proteomics.

[7]  T. Schumacher,et al.  High sensitivity of cancer exome-based CD8 T cell neo-antigen identification , 2014, Oncoimmunology.

[8]  Morten Nielsen,et al.  NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8–11 , 2008, Nucleic Acids Res..

[9]  G. Ciliberto,et al.  An efficient T-cell epitope discovery strategy using in silico prediction and the iTopia assay platform , 2012, Oncoimmunology.

[10]  Sébastien Lemieux,et al.  The MHC I immunopeptidome conveys to the cell surface an integrative view of cellular regulation , 2011, Molecular systems biology.

[11]  M. Nielsen,et al.  A combined prediction strategy increases identification of peptides bound with high affinity and stability to porcine MHC class I molecules SLA-1*04:01, SLA-2*04:01, and SLA-3*04:01 , 2016, Immunogenetics.

[12]  T. Blankenstein,et al.  Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice , 2015, Nature Biotechnology.

[13]  S. Hadrup,et al.  High frequency of T cells specific for cryptic epitopes in melanoma patients , 2013, Oncoimmunology.

[14]  D. Egan,et al.  High-throughput T-cell epitope discovery through MHC peptide exchange. , 2009, Methods in molecular biology.

[15]  Phillip Stafford,et al.  Scalable high-density peptide arrays for comprehensive health monitoring , 2014, Nature Communications.

[16]  Rong Fan,et al.  A Clinical Microchip for Evaluation of Single Immune Cells Reveals High Functional Heterogeneity in Phenotypically Similar T Cells Nih Public Access Author Manuscript Design Rationale and Detection Limit of the Scbc Online Methods Microchip Fabrication On-chip Secretion Profiling Supplementary Mater , 2022 .

[17]  N. Croft,et al.  Direct quantitation of MHC‐bound peptide epitopes by selected reaction monitoring , 2011, Proteomics.

[18]  S. Rosenberg,et al.  Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer , 2014, Science.

[19]  Gabriel A Kwong,et al.  Modular nucleic acid assembled p/MHC microarrays for multiplexed sorting of antigen-specific T cells. , 2009, Journal of the American Chemical Society.

[20]  Ellis L. Reinherz,et al.  Enhancement to the RANKPEP resource for the prediction of peptide binding to MHC molecules using profiles , 2004, Immunogenetics.

[21]  Chen Yanover,et al.  Large-scale characterization of peptide-MHC binding landscapes with structural simulations , 2011, Proceedings of the National Academy of Sciences.

[22]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[23]  T. Schumacher,et al.  Generation of peptide–MHC class I complexes through UV-mediated ligand exchange , 2006, Nature Protocols.

[24]  John T. Wilson,et al.  Discovering protective CD8 T cell epitopes--no single immunologic property predicts it! , 2015, Current opinion in immunology.

[25]  Mark M Davis,et al.  Combinatorial tetramer staining and mass cytometry analysis facilitate T-cell epitope mapping and characterization , 2013, Nature Biotechnology.

[26]  S. Maerkl,et al.  A Microfluidic Platform for High-Throughput Multiplexed Protein Quantitation , 2014, PloS one.

[27]  J. Castle,et al.  Mutant MHC class II epitopes drive therapeutic immune responses to cancer , 2015, Nature.

[28]  Sébastien Lemieux,et al.  MHC I-associated peptides preferentially derive from transcripts bearing miRNA response elements. , 2012, Blood.

[29]  J. Castle,et al.  Targeting the tumor mutanome for personalized vaccination therapy , 2012, Oncoimmunology.

[30]  T. Schumacher,et al.  Definition of Proteasomal Peptide Splicing Rules for High-Efficiency Spliced Peptide Presentation by MHC Class I Molecules , 2015, The Journal of Immunology.

[31]  J. E. Brewer,et al.  T cell receptor binding affinity governs the functional profile of cancer-specific CD8+ T cells , 2015, Clinical and experimental immunology.

[32]  H. Rammensee,et al.  SYFPEITHI: database for MHC ligands and peptide motifs , 1999, Immunogenetics.

[33]  Oliver Kohlbacher,et al.  Immunoinformatics and epitope prediction in the age of genomic medicine , 2015, Genome Medicine.

[34]  J. Gartner,et al.  Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. , 2015, The Journal of clinical investigation.

[35]  William W. Kwok,et al.  The Binding of Antigenic Peptides to HLA-DR Is Influenced by Interactions between Pocket 6 and Pocket 91 , 2009, The Journal of Immunology.

[36]  O. Lund,et al.  novel sequence representations Reliable prediction of T-cell epitopes using neural networks with , 2003 .

[37]  M. Stratton,et al.  Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Michael R Stratton,et al.  High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma , 2014, Nature Medicine.

[39]  Albert J R Heck,et al.  Expanding the detectable HLA peptide repertoire using electron-transfer/higher-energy collision dissociation (EThcD) , 2014, Proceedings of the National Academy of Sciences.

[40]  Mark Cobbold,et al.  Complementary IMAC enrichment methods for HLA-associated phosphopeptide identification by mass spectrometry , 2015, Nature Protocols.

[41]  S Walz,et al.  Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy , 2014, Leukemia.

[42]  Deborah Hix,et al.  The immune epitope database (IEDB) 3.0 , 2014, Nucleic Acids Res..

[43]  S. Rosenberg,et al.  An antigenic peptide produced by reverse splicing and double asparagine deamidation , 2011, Proceedings of the National Academy of Sciences.

[44]  Morten Nielsen,et al.  NetTepi: an integrated method for the prediction of T cell epitopes , 2014, Immunogenetics.

[45]  Morten Nielsen,et al.  Characterization of binding specificities of bovine leucocyte class I molecules: impacts for rational epitope discovery , 2014, Immunogenetics.

[46]  K. Cibulskis,et al.  Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. , 2014, Blood.

[47]  Hans-Georg Rammensee,et al.  HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL) , 2014, Proceedings of the National Academy of Sciences.

[48]  M. Mann,et al.  MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification , 2008, Nature Biotechnology.

[49]  Shabaz Mohammed,et al.  Sampling From the Proteome to the Human Leukocyte Antigen-DR (HLA-DR) Ligandome Proceeds Via High Specificity* , 2016, Molecular & Cellular Proteomics.

[50]  Maxim N. Artyomov,et al.  Tumor neoantigens: building a framework for personalized cancer immunotherapy. , 2015, The Journal of clinical investigation.

[51]  Morten Nielsen,et al.  Accurate pan-specific prediction of peptide-MHC class II binding affinity with improved binding core identification , 2015, Immunogenetics.

[52]  Morten Nielsen,et al.  Peptide‐MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity , 2012, European journal of immunology.

[53]  H Mamitsuka,et al.  Predicting peptides that bind to MHC molecules using supervised learning of hidden markov models , 1998, Proteins.

[54]  Morten Nielsen,et al.  MHC Class II epitope predictive algorithms , 2010, Immunology.

[55]  Morten Nielsen,et al.  Towards High-throughput Immunomics for Infectious Diseases: Use of Next-generation Peptide Microarrays for Rapid Discovery and Mapping of Antigenic Determinants* , 2015, Molecular & Cellular Proteomics.

[56]  O. Lund,et al.  An integrative approach to CTL epitope prediction: A combined algorithm integrating MHC class I binding, TAP transport efficiency, and proteasomal cleavage predictions , 2005, European journal of immunology.

[57]  Nicolai J. Birkbak,et al.  Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade , 2016, Science.

[58]  O. Lund,et al.  NetMHCpan, a Method for Quantitative Predictions of Peptide Binding to Any HLA-A and -B Locus Protein of Known Sequence , 2007, PloS one.

[59]  L. Stern,et al.  Measurement of Peptide Binding to MHC Class II Molecules by Fluorescence Polarization , 2014, Current protocols in immunology.

[60]  M. Nielsen,et al.  Peptide Binding to HLA Class I Molecules: Homogenous, High-Throughput Screening, and Affinity Assays , 2009, Journal of biomolecular screening.

[61]  T. Luft,et al.  Exogenous Peptides Presented by Transporter Associated with Antigen Processing (TAP)-Deficient and TAP-Competent Cells: Intracellular Loading and Kinetics of Presentation1 , 2001, The Journal of Immunology.

[62]  Z. Modrušan,et al.  Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing , 2014, Nature.

[63]  Søren Buus,et al.  Functional recombinant MHC class II molecules and high-throughput peptide-binding assays , 2009, Immunome research.

[64]  Morten Nielsen,et al.  Gapped sequence alignment using artificial neural networks: application to the MHC class I system , 2016, Bioinform..

[65]  Peter A van Veelen,et al.  Accurate quantitation of MHC-bound peptides by application of isotopically labeled peptide MHC complexes. , 2014, Journal of proteomics.

[66]  O. Lund,et al.  The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage , 2005, Immunogenetics.

[67]  Steven P Gygi,et al.  Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry , 2007, Nature Methods.

[68]  M. Donia,et al.  Broadening the repertoire of melanoma-associated T-cell epitopes , 2015, Cancer Immunology, Immunotherapy.

[69]  S. Rosenberg,et al.  Adoptive cell transfer as personalized immunotherapy for human cancer , 2015, Science.

[70]  N. Hacohen,et al.  Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.

[71]  Morten Nielsen,et al.  Prediction of epitopes using neural network based methods. , 2011, Journal of immunological methods.

[72]  Gajendra P. S. Raghava,et al.  ProPred: prediction of HLA-DR binding sites , 2001, Bioinform..

[73]  T. Schumacher,et al.  Neoantigens in cancer immunotherapy , 2015, Science.

[74]  Kenji Satou,et al.  PAAQD: Predicting immunogenicity of MHC class I binding peptides using amino acid pairwise contact potentials and quantum topological molecular similarity descriptors. , 2013, Journal of immunological methods.

[75]  J. Castle,et al.  Exploiting the mutanome for tumor vaccination. , 2012, Cancer research.

[76]  K. Cibulskis,et al.  Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes , 2015, Nature Biotechnology.

[77]  L. Jensen,et al.  Mass Spectrometry of Human Leukocyte Antigen Class I Peptidomes Reveals Strong Effects of Protein Abundance and Turnover on Antigen Presentation* , 2015, Molecular & Cellular Proteomics.

[78]  E. Mardis,et al.  Cancer Exome Analysis Reveals a T Cell Dependent Mechanism of Cancer Immunoediting , 2012, Nature.

[79]  Ilan Beer,et al.  Soluble plasma HLA peptidome as a potential source for cancer biomarkers , 2010, Proceedings of the National Academy of Sciences.

[80]  Thomas Lengauer,et al.  DynaPred: A structure and sequence based method for the prediction of MHC class I binding peptide sequences and conformations , 2006, ISMB.

[81]  T. Schumacher,et al.  Dissection of T-cell antigen specificity in human melanoma. , 2012, Cancer research.

[82]  Chin-Hsien Tai,et al.  Poor correlation between T-cell activation assays and HLA-DR binding prediction algorithms in an immunogenic fragment of Pseudomonas exotoxin A. , 2015, Journal of immunological methods.

[83]  Evan W. Newell,et al.  Higher Throughput Methods of Identifying T Cell Epitopes for Studying Outcomes of Altered Antigen Processing and Presentation , 2013, Front. Immunol..

[84]  M. Maeurer,et al.  Peptide Microarray-Based Identification of Mycobacterium tuberculosis Epitope Binding to HLA-DRB1*0101, DRB1*1501, and DRB1*0401 , 2009, Clinical and Vaccine Immunology.

[85]  T. Schumacher,et al.  TIL therapy broadens the tumor-reactive CD8+ T cell compartment in melanoma patients , 2012, Oncoimmunology.

[86]  Maxim N. Artyomov,et al.  Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens , 2014, Nature.

[87]  S. Rosenberg,et al.  Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions , 2014, Clinical Cancer Research.

[88]  Morten Nielsen,et al.  NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction , 2009, BMC Bioinformatics.

[89]  D. N. Perkins,et al.  Probability‐based protein identification by searching sequence databases using mass spectrometry data , 1999, Electrophoresis.

[90]  Oliver Kohlbacher,et al.  The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy. , 2015, Blood.

[91]  Søren Buus,et al.  Real-time, high-throughput measurements of peptide-MHC-I dissociation using a scintillation proximity assay. , 2011, Journal of immunological methods.

[92]  Sébastien Lemieux,et al.  Impact of genomic polymorphisms on the repertoire of human MHC class I-associated peptides , 2014, Nature Communications.

[93]  Ton N Schumacher,et al.  Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers , 2009, Nature Methods.

[94]  F. Dammacco,et al.  MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. , 2013, Journal of the National Cancer Institute.

[95]  C. Ponting,et al.  Sequencing depth and coverage: key considerations in genomic analyses , 2014, Nature Reviews Genetics.